Gene Therapy for Sickle Cell Disease and Thalassemia

Gene therapy is a way of treating certain genetic disorders, including inherited blood disorders such as sickle cell disease and thalassemia. It is an advanced type of treatment that works by correcting defective genes or by giving you a working copy of that gene.

Genetic diseases are caused by a mutation in a gene which stops it from working or causes it to produce faulty proteins. Gene therapy is often only needed once to allow your body to produce proteins that allow it to work properly.

Gene therapy can be used as an effective treatment for sickle cell disease and thalassemia. Treatment helps the body to produce healthy red blood cells, which reduces the complications of these disorders and improves overall quality of life. Gene therapy is also being studied as a treatment for other blood disorders, such as certain clotting disorders, immune deficiencies and blood cancers.

How does gene therapy for sickle cell disease and thalassemia work?

Gene therapy for hematological disorders such as sickle cell and thalassemia uses techniques called gene editing or insertion. The treatments involve modifying the patient’s own hemopoietic stem cells (the cells responsible for making the red blood cells) so that they produce healthy cells.

The steps involve:

• Collecting stem cells: Hemopoietic stem cells are collected from the patient’s blood or bone marrow.
• Gene correction: The defective gene is corrected or replaced in a laboratory. This is done using gene-editing tools, such as:
  • CRISPR-Cas9: A precise molecular ‘scissor’ that can cut and repair specific DNA sequences
  • Zinc finger nucleases and TALENs: Other targeted gene-editing technologies.
  • Gene addition: Adding a healthy copy of the gene to restore normal hemoglobin production
• Delivery of the corrected gene: This relies on something called vectors. Vectors are the vehicles that deliver the genetic material into the stem cell. Vectors used may include:
  • Lentiviruses: Modified viruses that integrate new genes into the stem cell DNA.
  • Adeno-associated viruses (AAVs): Non-replicating viruses used for precise gene delivery.
• Reinfusion: The corrected stem cells are then returned to the patient. They settle in the bone marrow and begin producing healthy red blood cells, which can prevent anemia, pain crises, and the need for frequent transfusions.

Who can benefit from gene therapy?

Gene therapy represents a safe and effective treatment for inherited blood disorders including sickle cell disease and thalassemia. It targets the underlying cause of the disease, rather than just addressing the symptoms and offers the possibility of long-term improvement, and in some cases a cure.

For those living with sickle cell disease, gene therapy can reduce pain crises, anemia, and hospital admissions.

For people with thalassemia, gene therapy can reduce or eliminate the need for regular blood transfusions.

Gene therapy may also have benefits for people living with other blood disorders, such as clotting disorders, immune deficiencies, and certain blood cancers.

Gene therapy improves quality of life, reduces complications and dependence on ongoing treatments. It represents an exciting advancement in the treatment of sickle cell disease and thalassemia, and offers patients hope for a healthier and more independent life.